1. The rising cost of specialty drugs drove spending increases for people with multiple sclerosis Author(s): Johnson, Bill, author Publication: Washington, DC : Health Care Cost Institute, April 2018 Subject(s): Drug CostsHealth Expenditures -- statistics & numerical dataHealth Expenditures -- trendsMultiple Sclerosis -- economicsMultiple Sclerosis -- drug therapyDihydroorotate Oxidase -- antagonists & inhibitorsDimethyl Fumarate -- economicsFingolimod Hydrochloride -- economicsForecastingGlatiramer Acetate -- economicsInterferon beta-1a -- economicsInterferon beta-1b -- economicsHumansUnited States
